(Information sent by the signatory company)
– Ajinomoto Bio-Pharma Services Earns Six ‘CDMO Leadership Awards’, Further Establishing Its Excellence in the Industry
SAN DIEGO and TOKYO and WETTEREN, Belgium, March 12, 2024 /PRNewswire/ –Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Awards Leadership Awards in the six categories: capabilities, compatibility, experience, quality, reliability and service for both the general and large pharmaceutical group of respondents. Of the awards listed, Aji Bio-Pharma received additional recognition as CDMO Leadership Award Champion in the Service category for the Small Pharma respondent group by scoring high performance compared to the weighted average of other CDMOs evaluated.
The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader and Industry Standard Research. Respondents evaluated 98 contract manufacturers across 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Respondents only evaluate companies with which they have worked on an outsourced project in the last 18 months. This level of qualification ensures that survey responses are based on actual engagement with contract manufacturers and clear experiential data to recognize top outsourcing partners.
“We are honored to be recognized in all categories by our partners. With every investment in technology, quality and facilities, we elevate our capabilities, ensuring we meet and exceed the needs of our customers. We pride ourselves on not only meeting the expectations of and we will serve countless patients in the years to come,” said Yasuyuki Otake, corporate executive and general manager of the Biopharmaceutical Services Department.
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with plants in Belgium, the United States, Japan and India, offering comprehensive development, cGMP manufacturing and aseptic filling finishing services for APIs and small molecule intermediates and big. Ajinomoto Bio-Pharma Services offers a wide range of innovative platforms and capabilities from preclinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, antibody-drug conjugations (ADC), high-potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet the needs of its customers. More information: www.AjiBio-Pharma.com
Logo – https://mma.prnewswire.com/media/751177/…
View original content: https://www.prnewswire.com/news-releases/ajinomoto-bio-pharma-services-obtiene-seis-premios-al-liderazgo-cdmo-302087064.html
